---
reference_id: "PMID:35660797"
title: "PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer."
authors:
- Cercek A
- Lumish M
- Sinopoli J
- Weiss J
- Shia J
- Lamendola-Essel M
- El Dika IH
- Segal N
- Shcherba M
- Sugarman R
- Stadler Z
- Yaeger R
- Smith JJ
- Rousseau B
- Argiles G
- Patel M
- Desai A
- Saltz LB
- Widmar M
- Iyer K
- Zhang J
- Gianino N
- Crane C
- Romesser PB
- Pappou EP
- Paty P
- Garcia-Aguilar J
- Gonen M
- Gollub M
- Weiser MR
- Schalper KA
- Diaz LA Jr
journal: N Engl J Med
year: '2022'
doi: 10.1056/NEJMoa2201445
content_type: abstract_only
---

# PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.
**Authors:** Cercek A, Lumish M, Sinopoli J, Weiss J, Shia J, Lamendola-Essel M, El Dika IH, Segal N, Shcherba M, Sugarman R, Stadler Z, Yaeger R, Smith JJ, Rousseau B, Argiles G, Patel M, Desai A, Saltz LB, Widmar M, Iyer K, Zhang J, Gianino N, Crane C, Romesser PB, Pappou EP, Paty P, Garcia-Aguilar J, Gonen M, Gollub M, Weiser MR, Schalper KA, Diaz LA Jr
**Journal:** N Engl J Med (2022)
**DOI:** [10.1056/NEJMoa2201445](https://doi.org/10.1056/NEJMoa2201445)

## Content

1. N Engl J Med. 2022 Jun 23;386(25):2363-2376. doi: 10.1056/NEJMoa2201445. Epub 
2022 Jun 5.

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.

Cercek A(1), Lumish M(1), Sinopoli J(1), Weiss J(1), Shia J(1), Lamendola-Essel 
M(1), El Dika IH(1), Segal N(1), Shcherba M(1), Sugarman R(1), Stadler Z(1), 
Yaeger R(1), Smith JJ(1), Rousseau B(1), Argiles G(1), Patel M(1), Desai A(1), 
Saltz LB(1), Widmar M(1), Iyer K(1), Zhang J(1), Gianino N(1), Crane C(1), 
Romesser PB(1), Pappou EP(1), Paty P(1), Garcia-Aguilar J(1), Gonen M(1), Gollub 
M(1), Weiser MR(1), Schalper KA(1), Diaz LA Jr(1).

Author information:
(1)From the Division of Solid Tumor Oncology (A.C., M.L., J. Sinopoli, J.W., 
M.L.-E., I.H.E.D., N.S., M.S., R.S., Z.S., R.Y., B.R., G.A., M.P., A.D., L.B.S., 
L.A.D.) and the Departments of Pathology (J. Shia), Surgery (J.J.S., M.W., 
E.P.P., P.P., J.G.-A., M.R.W.), Radiation Oncology (C.C., P.B.R.), Epidemiology 
and Biostatistics (M. Gonen), and Radiology (M. Gollub), Memorial Sloan 
Kettering Cancer Center, New York; and the Department of Pathology, Yale 
University School of Medicine, New Haven, CT (K.I., J.Z., N.G., K.A.S.).

Comment in
    N Engl J Med. 2022 Jun 23;386(25):2425-2426. doi: 10.1056/NEJMe2204282.
    Nat Rev Clin Oncol. 2022 Aug;19(8):494. doi: 10.1038/s41571-022-00661-x.
    Strahlenther Onkol. 2022 Dec;198(12):1116-1118. doi: 
10.1007/s00066-022-01990-7.
    N Engl J Med. 2022 Sep 1;387(9):854-855. doi: 10.1056/NEJMc2209706.
    N Engl J Med. 2022 Sep 1;387(9):855. doi: 10.1056/NEJMc2209706.
    Signal Transduct Target Ther. 2022 Oct 10;7(1):361. doi: 
10.1038/s41392-022-01216-3.
    Int J Radiat Oncol Biol Phys. 2023 Mar 1;115(3):545-552. doi: 
10.1016/j.ijrobp.2022.10.022.
    Eur J Cancer. 2023 Nov;194:113356. doi: 10.1016/j.ejca.2023.113356.

BACKGROUND: Neoadjuvant chemotherapy and radiation followed by surgical 
resection of the rectum is a standard treatment for locally advanced rectal 
cancer. A subset of rectal cancer is caused by a deficiency in mismatch repair. 
Because mismatch repair-deficient colorectal cancer is responsive to programmed 
death 1 (PD-1) blockade in the context of metastatic disease, it was 
hypothesized that checkpoint blockade could be effective in patients with 
mismatch repair-deficient, locally advanced rectal cancer.
METHODS: We initiated a prospective phase 2 study in which single-agent 
dostarlimab, an anti-PD-1 monoclonal antibody, was administered every 3 weeks 
for 6 months in patients with mismatch repair-deficient stage II or III rectal 
adenocarcinoma. This treatment was to be followed by standard chemoradiotherapy 
and surgery. Patients who had a clinical complete response after completion of 
dostarlimab therapy would proceed without chemoradiotherapy and surgery. The 
primary end points are sustained clinical complete response 12 months after 
completion of dostarlimab therapy or pathological complete response after 
completion of dostarlimab therapy with or without chemoradiotherapy and overall 
response to neoadjuvant dostarlimab therapy with or without chemoradiotherapy.
RESULTS: A total of 12 patients have completed treatment with dostarlimab and 
have undergone at least 6 months of follow-up. All 12 patients (100%; 95% 
confidence interval, 74 to 100) had a clinical complete response, with no 
evidence of tumor on magnetic resonance imaging, 
18F-fluorodeoxyglucose-positron-emission tomography, endoscopic evaluation, 
digital rectal examination, or biopsy. At the time of this report, no patients 
had received chemoradiotherapy or undergone surgery, and no cases of progression 
or recurrence had been reported during follow-up (range, 6 to 25 months). No 
adverse events of grade 3 or higher have been reported.
CONCLUSIONS: Mismatch repair-deficient, locally advanced rectal cancer was 
highly sensitive to single-agent PD-1 blockade. Longer follow-up is needed to 
assess the duration of response. (Funded by the Simon and Eve Colin Foundation 
and others; ClinicalTrials.gov number, NCT04165772.).

Copyright Â© 2022 Massachusetts Medical Society.

DOI: 10.1056/NEJMoa2201445
PMCID: PMC9492301
PMID: 35660797 [Indexed for MEDLINE]